Near-critical adsorption of CO2 on 13X zeolite and N2O onsilicagel: lack of evidence of critical phenomena

The excess adsorption of CO2 on 13X zeolite and of N2O on silica gel has been studied at high pressure using a magnetic suspension balance, i.e. a gravimetric method. Recently, a detailed study on the density distribution in the measuring cell of the magnetic suspension balance showed that a proper approach to thermostatting the unit should be used in order to obtain reliable and accurate excess adsorption measurements. This is particularly important in the vicinity of the critical point of the fluid, where the density is strongly dependent on pressure and temperature. In the past, several effects were observed in our laboratory when measuring near-critical adsorption on 13X zeolite and on silica gel, namely critical adsorption and critical depletion. In the present study, these effects have been checked using the balance in the new thermostatting configuration, and the conclusion can be drawn that the accuracy of the measurement is not sufficient to prove that they indeed occur. More accurate adsorption data for the two systems have been measured and reporte

Reliable measurement of near-critical adsorption by gravimetric method

A gravimetric apparatus is used to measure the excess adsorption at high pressure. The equipment consists of a Rubotherm magnetic suspension balance, which allows to measure also the density of the fluid. In order to obtain the excess adsorbed amount, the measured weight has to be corrected with a buoyancy term, for which the density of the adsorbing fluid has to be known at each experimental conditions. Therefore the homogeneity of density in the high-pressure cell plays a fundamental role in determining the accuracy of the measured excess adsorbed amounts. This paper is intended to show the impact of the actual approach to thermostating the unit on the density distribution of the adsorbing fluid inside the high-pressure cell. Namely, by changing the inlet position of the heating fluid, large differences in the measured excess adsorption are produced. The closer to the critical point of the fluid, the stronger are these differences. An optimum configuration for our measuring device has been found and it has been used to study the adsorption of carbon dioxide (CO2) on Filtrasorb 400 activated carbon at supercritical and near-critical condition

Imaging mechanisms analysis of compact digital holographic microscope for microparticles measurement

AbstractConventional optical microscopy suffers from small depth of focus due to its high numerical aperture and magnification of the microscope objective. In comparison, digital in-line holographic microscopy (DIHM) provides information about the entire 3D volume through numerical reconstruction of the single hologram at several depths. This advantage makes DIHM an effective tool for the measurement of microparticles in suspension. Recently, our group has demonstrated the potential of DIHM for accurate measurement of particles with sizes ranging from 40 microns to a few millimetres. In this paper, the applicability of DIHM is extended for measurement of near-micron sized particles. A compact digital holographic microscope with a single microscope objective is presented. The system imaging mechanisms of the microscope is analyzed first and the recording distance of digital hologram is calculated using spatial frequency analysis. Then the system magnification, lateral resolution and depth resolution are analyzed in terms of the hologram recording distance. Finally, the characterization of microparticles with a diameter of 1 micron and 10 microns is demonstrated with the compact setup. The experimental results show the efficiency and accuracy of this method with a measured error less than 1.55% in the diameter of certified particles

Techno-economic Assessment of Optimised Vacuum Swing Adsorption for Post-Combustion CO2 capture from Steam-Methane Reformer Flue Gas

This study focuses on the techno-economic assessment integrated with detailed optimisation of a four step vacuum swing adsorption (VSA) process for post-combustion CO2 capture and storage (CCS) from steam-methane reformer dried flue gas containing 20 mol% CO2. The comprehensive techno-economic optimisation model developed herein takes into account VSA process model, peripheral component models, vacuum pump performance, scale-up, process scheduling and a thorough cost model. Three adsorbents, namely, Zeolite 13X (current benchmark material for CO2 capture) and two metal–organic frameworks, UTSA-16 (widely studied metal–organic framework for CO2 capture) and IISERP MOF2 (good performer in recent findings) are optimised to minimise the CO2 capture cost. Monoethanolamine (MEA)-based absorption technology serves as a baseline case to assess and compare optimal techno-economic performances of VSA technology for three adsorbents. The results show that the four step VSA process with IISERP MOF2 outperforms other two adsorbents with a lowest CO2 capture cost (including flue gas pre-treatment) of 33.6 € per tonne of CO2 avoided and an associated CO2 avoided cost of 73.0 € per tonne of CO2 avoided. Zeolite 13X and UTSA-16 resulted in CO2 avoided costs of 90.9 and 104.9 € per tonne of CO2 avoided, respectively. The CO2 avoided costs obtained for the VSA technology remain higher than that of the baseline MEA-based absorption process which was found to be 66.6 € per tonne of CO2 avoided. The study also demonstrates the importance of using cost as means of evaluating the separation technique compared to the use of process performance indicators. Accounting for the efficiency of vacuum pumps and the cost of novel materials such as metal–organic frameworks is highlighted. © 2020 Elsevier B.V.acceptedVersio

Study of Agricultural Market in India with Illustration of Business Opportunity

The role of agriculture in India has been not just to produce food but to sustain and contribute towards overall socio-economic development in rural societies. Overregulation of agriculture along with lack of infrastructural facilities and small fragmented unproductive landholdings has increased costs, price risks and uncertainty. The agricultural system has traditionally been unfair to farmers as well as the end consumers. This study will analyze the agricultural marketing system in India from the perspective of issues faced by farmers, traders and food processors. These issues include information asymmetry, excessive margins in price at each level of the supply chain, limited reach of technology in rural India, post harvest wastage etc. It has also been characterised by lack of infrastructure, inadequate marketing channels to the farmers and archaic government policies that prevented investment into this sector for a long time. Indian agriculture has changed a lot in past few years, but still not kept the pace due to existence of these issues. The presence of these issues in Indian agricultural market is rather undeveloped and inefficient characterised by a long supply chain, lack of transparency on pricing and quality issues. The purpose of this report is to analyse these challenges and opportunities while providing recommendations from the agribusiness perspective. Price variations and availability of the produce in the market is analysed with the help of surveys, interviews and latest price data available on the web-portals. This report also highlights the initiatives taken by two firms (PepsiCo and ITC eChoupal) for empowering farmers and shortening the long supply chain for marketing agricultural produce. It sets out the scope, proposed objectives and initial research of information for understanding the potential synergies in context with the Indian agricultural market

Potential Role of Plant Growth Regulators in Administering Crucial Processes Against Abiotic Stresses

Plant growth regulators are naturally biosynthesized chemicals in plants that influence physiological processes. Their synthetic analogous trigger numerous biochemical and physiological processes involved in the growth and development of plants. Nowadays, due to changing climatic scenario, numerous biotic and abiotic stresses hamper seed germination, seedling growth, and plant development leading to a decline in biological and economic yields. However, plant growth regulators (PGRs) can potentially play a fundamental role in regulating plant responses to various abiotic stresses and hence, contribute to plant adaptation under adverse environments. The major effects of abiotic stresses are growth and yield disturbance, and both these effects are directly overseen by the PGRs. Different types of PGRs such as abscisic acid (ABA), salicylic acid (SA), ethylene (ET), and jasmonates (JAs) are connected to boosting the response of plants to multiple stresses. In contrast, PGRs including cytokinins (CKs), gibberellins (GAs), auxin, and relatively novel PGRs such as strigolactones (SLs), and brassinosteroids (BRs) are involved in plant growth and development under normal and stressful environmental conditions. Besides, polyamines and nitric oxide (NO), although not considered as phytohormones, have been included in the current review due to their involvement in the regulation of several plant processes and stress responses. These PGRs are crucial for regulating stress adaptation through the modulates physiological, biochemical, and molecular processes and activation of the defense system, upregulating of transcript levels, transcription factors, metabolism genes, and stress proteins at cellular levels. The current review presents an acumen of the recent progress made on different PGRs to improve plant tolerance to abiotic stress such as heat, drought, salinity, and flood. Moreover, it highlights the research gaps on underlying mechanisms of PGRs biosynthesis under stressed conditions and their potential roles in imparting tolerance against adverse effects of suboptimal growth conditions.Fil: Sabagh, Ayman EL. Kafrelsheikh University; EgiptoFil: Mbarki, Sonia. National Institute Of Research In Rural Engineering; TúnezFil: Hossain, Akbar. Bangladesh Agricultural Research Institute; BangladeshFil: Iqbal, Muhammad Aamir. University Of Poonch Rawalakot; PakistánFil: Islam, Mohammad Sohidul. Hajee Mohammad Danesh And Technology University; BangladeshFil: Raza, Ali. Fujian Agriculture And Forestry University; ChinaFil: Llanes, Analia Susana. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Investigaciones Agrobiotecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Investigaciones Agrobiotecnologicas.; ArgentinaFil: Reginato, Mariana Andrea. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Investigaciones Agrobiotecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Investigaciones Agrobiotecnologicas.; ArgentinaFil: Rahman, Md Atikur. Grassland And Forage Division National Institute; Corea del SurFil: Mahboob, Wajid. Nuclear Institute Of Agriculture,; PakistánFil: Singhal, Rajesh Kumar. Indian Council Of Agricultural Research; IndiaFil: Kumari, Arpna. Guru Nanak Dev University; IndiaFil: Rajendran, Arvind. Vellore Institute Of Technology; IndiaFil: Wasaya, Allah. Bahauddin Zakariya University; PakistánFil: Javed, Talha. Fujian Agriculture And Forestry University; JapónFil: Shabbir, Rubab. University Of Poonch Rawalakot; PakistánFil: Rahim, Junaid. University Of Çukurova; PakistánFil: Barutçular, Celaleddin. Institute Of Crop Science And Resource Conservation; AlemaniaFil: Habib Ur Rahman, Muhammad. Sichuan Agricultural University; ChinaFil: Raza, Muhammad Ali. Sichuan Agricultural University; ChinaFil: Ratnasekera, Disna. University Of Ruhuna; Sri LankaFil: Konuskan l, Ömer. Mustafa Kemal University; TurquíaFil: Hossain, Mohammad Anwar. Bangladesh Agricultural Research Institute; BangladeshFil: Meena, Vijay Singh. Indian Council Of Agricultural Research; IndiaFil: Ahmed, Sharif. Bangladesh Agricultural Research Institute; BangladeshFil: Ahmad, Zahoor. Bangladesh Wheat And Maize Research Institute; BangladeshFil: Mubeen, Muhammad. Sichuan Agricultural University; ChinaFil: Singh, Kulvir. Punjab Agricultural University; IndiaFil: Skalicky, Milan. Czech University Of Life Sciences Prague; República ChecaFil: Brestic, Marian. Slovak University Of Agriculture; EslovaquiaFil: Sytar, Oksana. Slovak University Of Agriculture; EsloveniaFil: Karademir, Emine. Siirt University; TurquíaFil: Karademir, Cetin. Siirt University; TurquíaFil: Erman, Murat. Siirt University; TurquíaFil: Farooq, Muhammad. College Of Agricultural And Marine Sciences Sultan; Omá

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

The original version of this article unfortunately contained a mistake